Skip to content

FITC Antisera to Human IgA

by Amico Lab, Inc.

510(k) K822675

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 6 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 6 Oct 2026. What this means

Regulatory status

as of registry sync 6 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK822675 Date17 Nov 1982ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 6 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA Product Code
DFH
Device Class
Class II
Regulation
21 CFR Part 866.5550
Advisory Committee
Immunology
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

This device is a fluorescein isothiocyanate (FITC)-conjugated antisera used for the identification and quantification of human immunoglobulin A (IgA) in immunological assays. It functions as a fluorescent marker in serological testing, enabling visualization under ultraviolet light for diagnostic purposes in immunology.

The FITC Antisera to Human IgA is supplied as a reagent for in vitro diagnostic use, intended for laboratory settings. It is classified under product code DFH and has received FDA 510(k) clearance (K822675) as substantially equivalent to a predicate device. No information regarding sterility, single-use, or MRI safety is provided in the available data.

Other devices from Amico Lab, Inc.

See all devices from Amico Lab, Inc. →

Questions

AI-generated answers, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What is the primary use of the FITC Antisera to Human IgA in a clinical setting?

    This device is designed for identifying and quantifying human immunoglobulin A (IgA) in immunological assays. It works as a fluorescent marker, allowing samples to be visualized under ultraviolet light during serological testing, which helps in diagnosing conditions related to immunology.

  • How is the FITC Antisera to Human IgA supplied, and is it intended for single-use or reuse?

    The product is supplied as a reagent for in vitro diagnostic use in laboratory settings. While the data does not explicitly state whether it is single-use or reusable, it is typically standard practice for fluorescent antisera to be single-use due to potential degradation of the fluorescent marker over repeated use.

  • What regulatory pathway was followed for the FDA clearance of this device?

    The FITC Antisera to Human IgA received FDA 510(k) clearance under the traditional review pathway, with a decision date of November 17, 1982. It was determined to be substantially equivalent to a predicate device, as indicated by the clearance type and decision description.

  • Is there any information provided about the sterility of this product?

    The available data does not specify whether the FITC Antisera to Human IgA is sterile or not. If sterility is a critical requirement for your application, you should verify this directly with the manufacturer, Amico Lab, Inc.

  • What medical specialty is primarily associated with the use of this device?

    The device is classified under the medical specialty of immunology, as indicated by the advisory committee (IM) and the product code (DFH). This aligns with its use in serological testing for immunoglobulin A.